// App-Quantinova.ai

OP0170 (2021) : DECLINE IN FORCED VITAL CAPACITY (FVC) IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) WITH AND WITHOUT DYSPNOEA: DATA FROM THE SENSCIS TRIAL

Researchers

Presenter

  • E. Volkmann

Principal Investigators

  • M. Kreuter

  • A. M. Hoffmann-Vold

  • M. Wijsenbeek

  • V. Smith

  • D. Khanna

  • C. Denton

  • W. Wuyts

  • C. Miede

  • M. Alves

  • S. Sambevski

  • Y. Allanore

Medical Centers

  • University of California, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology, Los Angeles, CA, United States of America

  • Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Heidelberg, Germany

  • Oslo University Hospital, Department of Pathology, Oslo, Norway

  • Erasmus MC, University Medical Centre, Department of Respiratory Medicine, Rotterdam, Netherlands

  • Ghent University Hospital, Department of Rheumatology and Internal Medicine, Ghent, Belgium

  • University of Michigan Health System, Department of Internal Medicine, Ann Arbor, United States of America

  • University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom

  • University Hospitals Leuven, Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, Leuven, Belgium

  • Mainanalytics GmbH, Statistics, Sulzbach (Taunus), Germany

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • , Descartes University, APHP, Cochin Hospital, Department of Rheumatology A, Paris, Italy

Locations

  • United States

  • Germany

  • Norway

  • Netherlands

  • Belgium

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Dyspnea

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved